Sign in
TSHA Stock Price, Chart, Stats & News
Taysha Gene Therapies, Inc.
Save
1.61B
Market cap
–
Current P/E
–
Forward P/E
TSHA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 94.01% |
Operating margin | -1130.65% |
Pretax margin | -1115.27% |
Net margin | -1115.27% |
Effective tax rate | – |
ROA | -31.75% |
ROE | -56.64% |
D/E | 0.07x |
Interest coverage ratio | -1753.94x |
TSHA valuation
P/E | – |
P/S | 104.18x |
P/B | 5.27x |
P/CF | -13.98x |
P/FCF | -10.85x |
P/OCF | -13.98x |
PEG | -4.18x |
EV multiple | -12.19x |
About
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis.
Similar securities
Based on sector and market capitalization
Report issue